Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
1/5 보강
Gastric cancer is the fifth leading cause of cancer-related deaths worldwide.
APA
Ajani JA, D'Amico TA, et al. (2025). Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.. Journal of the National Comprehensive Cancer Network : JNCCN, 23(5), 169-191. https://doi.org/10.6004/jnccn.2025.0022
MLA
Ajani JA, et al.. "Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 23, no. 5, 2025, pp. 169-191.
PMID
40341199 ↗
Abstract 한글 요약
Gastric cancer is the fifth leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histologic type. Gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage. Systemic therapy can provide palliation, improve survival, and enhance the quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing has had a significant impact on clinical practice and patient care. Targeted therapies have demonstrated encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. This selection from the NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer highlights recommendations for biomarker testing and discusses updates for the treatment of advanced disease, including peritoneal carcinoma as only disease and unresectable locally advanced, recurrent, or metastatic disease.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (3)
- Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons.
- Comparative efficacy and safety of tislelizumab and other programmed cell death protein 1 inhibitors in first-line treatment of advanced gastroesophageal cancers: a systematic review and network meta-analysis.
- Tislelizumab efficacy and safety compared to other anti-PD-1s: a network meta-analysis of first-line therapies for unresectable, locally advanced or metastatic esophageal squamous cell carcinoma.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.